THE Federal Govt has accepted the latest advice from the Australian Technical Advisory Group on Immunisation on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program.
The new XBB 1.5 vaccines have been found to provide modest improved protection against the COVID-19 strains circulating in the community.
The XBB 1.5 vaccines will be available along with the existing bivalent vaccines.
Pfizer's monovalent XBB.1.5 vaccine will be available for use in eligible people aged five years and older, while the Moderna monovalent XBB.1.5 vaccine can be used for those aged 12 years and older.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Nov 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Nov 23
